Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 14;1(24):2281-2294.
doi: 10.1182/bloodadvances.2017009829.

The role of targeted therapy in the management of patients with AML

Alexander E Perl  1
Affiliations
Review

The role of targeted therapy in the management of patients with AML

Alexander E Perl. Blood Adv. .

Abstract

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.E.P. is on the Board of Directors or an advisory committee for Asana Biosciences and Actinium Pharmaceuticals and has consulted for Daiichi Sankyo, Astellas, Novartis, Pfizer, Arog, Seattle Genetics, Asana Biosciences, and Actinium Pharmaceuticals. Off-label drug use: This presentation includes novel agents in clinical development that do not yet have label indications in acute myeloid leukemia (AML). The use of sorafenib, azacitidine, or decitabine for AML therapy is off label.

Figures

Figure 1.
Figure 1.
The flow diagram shows how integration of molecular diagnostics and NGS potentially can rapidly segregate patients into groups for whom particular and increasingly targeted therapies have shown benefit or are currently being tested. ATRA, all-trans retinoic acid; ATO, arsenic trioxide; CBF, core-binding factor; FISH, fluorescent in situ hybridization; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; MRC, myelodysplasia-related change; RT-PCR, reverse transcriptase-polymerase chain reaction; t-AML, therapy-related AML; 713, cytarabine by continuous infusion (7 doses) plus anthracycline (3 doses).
See this image and copyright information in PMC

References

    1. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol. 2013;97(6):683-694. - PubMed
    1. Levis M, Brown P, Smith BD, et al. . Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477-3483. - PMC - PubMed
    1. Pratz KW, Cortes J, Roboz GJ, et al. . A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009;113(17):3938-3946. - PMC - PubMed
    1. Cortes JE, Kantarjian H, Foran JM, et al. . Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681-3687. - PMC - PubMed
    1. Cortes JE, Perl AE, Dombret H, et al. . Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. 2012;120(21):48.